Advertisement

Picture Berlin Partner Voices Martin Rahmel TU Berlin GreenChem 650x100px
Organisation › Details

Vaccibody AS (Euronext Growth Oslo: VACC)

Vaccibody is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies. The Company is using the Vaccibody technology platform to generate best-in-class therapeutics against cancers and infectious diseases with a high unmet medical need. Vaccibody is developing cutting-edge, targeted DNA vaccines for clinical use, based on a deep understanding of immunological principles. Vaccibody’s vaccines specifically target Antigen Presenting Cells (APC), which are essential for inducing rapid, strong and specific immune responses and elicit efficacious clinical responses. By intelligent design, Vaccibody’s vaccines can be tailored to induce the desired immune response profile correlating with protection for each specific disease with any given antigen. Hence, the Vaccibody vaccine platform has the potential to address many disease areas with a high unmet medical need such as cancer and infectious diseases. In addition, Vaccibody has collaborations with Roche and Nektar Therapeutics. Vaccibody’s shares are traded on NOTC, a marketplace for unlisted shares managed by NOTC AS, which is owned 100% by Oslo Børs ASA, the Oslo Stock Exchange. *

 

Period Start 2012-08-13 existent
Period End 2021-11-30 renamed
  Today Nykode Therapeutics AS (Euronext Growth Oslo: NYKD)
  Successor Nykode Therapeutics AS (Euronext Growth Oslo: NYKD)
Products Industry vaccine technology
  Industry 2 cancer vaccine
Persons Person Engsig, Michael (Vaccibody 202010 CEO)
  Person 2 Bonde, Martin (Vaccibody 201508– CEO before EpiTherapeutics ApS + Aros Pharma ApS + Natimmune AS + Combio AS)
     
Region Region Oslo
  Country Norway
  Street 21 Gaustadalléen
Oslo Research Park
  City 0349 Oslo
  Tel +47-22-958193
    Address record changed: 2021-11-23
     
Basic data Employees n. a.
     
    * Document for »About Section«: Vaccibody AS. (10/1/20). "Press Release: Vaccibody Enters into Worldwide License and Collaboration Agreement with Genentech, a Member of the Roche Group, to Develop Individualized Neoantigen Cancer Vaccines". Oslo.
     
   
Record changed: 2024-02-12

Advertisement

Picture Sino Biological Symposium Antibody Engineering Leipzig 650x200px

More documents for Vaccibody AS (Euronext Growth Oslo: VACC)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Sino Biological Symposium Antibody Engineering Leipzig 650x200px




» top